MedTrace Logo

Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression

NCT06751784 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-12-12

No results posted yet for this study

Summary

Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild to moderate depression

Conditions

  • Working Memory
  • Mild to Moderate Depression

Interventions

DRUG

Fampridine SR

Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.

OTHER

Placebo

no active substance

Sponsors & Collaborators

  • Clinical Trial Unit, University Hospital Basel, Switzerland

    collaborator OTHER

  • University of Basel

    lead OTHER

Principal Investigators

  • Dominique de Quervain, Prof. MD · Research Cluster Molecular and Cognitive Neurosciences

  • Andreas Papassotiropoulos, Prof.MD · Research Cluster Molecular and Cognitive Neurosciences

  • Annette Bruehl, Prof.MD · Zentrum für Affektive -, Stress- und Schlafstörungen & Zentrum für Alterspsychiatrie UPK Basel

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06751784 on ClinicalTrials.gov